Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 1, 2016

View Archived Issues

University of Cape Town researchers identify new antimalarial candidate

Starpharma and AstraZeneca enter drug delivery program collaboration

First patient treated in International Stem Cell's phase I study of ISC-hpNSC stem cell therapy

Bristol-Myers Squibb reviews pipeline highlights of second quarter 2016

Preclinical characterization of M1 allosteric modulator SUVN-I4035 in AD models

Boehringer Ingelheim patents sodium channel blockers

Constellation Pharmaceuticals and Genentech report demethylase 2B inhibitors

Merck & Co. discloses BTK inhibitors

Chengdu Bestchiralbio introduces LDL-receptor expression enhancers

Phase II ECOSPOR study of microbiome therapeutic SER-109 fails to meet primary endpoint

Amgen highlights key events of second quarter 2016

Shire's SHP-626 awarded FDA fast track designation

Merck & Co.'s Zepatier receives marketing authorization in Europe

Sunovion Pharmaceuticals submits NDA for SUN-101/eFlow for COPD

Edge Therapeutics announces treatment of first patient in NEWTON 2 study of EG-1962

EMA accepts for review MAA for sarilumab

Taiho seeks approval of additional indications for Zosyn in Japan

Diamyd Medical signs agreement regarding ongoing GABA/GAD trial

Researchers develop software tool that could facilitate and advance drug development

Increased p-cresyl sulfate level is independent predictor of poor outcome in heart failure

NxGEN MDx and NX Prenatal collaborate on the development of a test to identify preterm birth risk

Setmelanotide as potential novel treatment of proopiomelanocortin deficiency

FDA issues complete response letter for ADMA Biologics' BLA for RI-002

PAF receptor activity could mediate aberrant connectivity in epileptogenesis

GSK and Verily to establish a new bioelectronic medicines company

Therapeutic potential of targeting ADAM33 in asthma

FDA approves Dysport for the treatment of lower limb spasticity in children

Chi-Med and AstraZeneca amend savolitinib codevelopment agreement

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.